Table 2.
Therapeutic options | Uses | Suggested doses | Remarks |
---|---|---|---|
Danazol Stanozolol Oxandrolone (Weak androgens) |
Short term & Long term prophylaxis |
Danazol - STP: 2.5–10 mg/kg/day (maximum 600 mg/day). LTP: 2.5–5 mg/kg/day (maximum 200 mg/day). | Easily available. Undesirable virilising effect, weight gain, acne, headaches, menstrual irregularities, depression. |
Tranexamic acid Epsilon aminocaproic acid | Short term & Long term prophylaxis |
Tranexamic acid: 20–50 mg/kg/day in 2 or 3 divided doses (maximum 3–6 g/day). | Can be used in pregnancy if benefits outweigh risk (category B) |
FFP (fresh frozen plasma)/ SDP (solvent detergent plasma) |
Short term prophylaxis Acute treatment |
10 ml/kg/dose | Easily available, inexpensive. Concern of infections with regular use. |
C1 esterase inhibitors | pdC1-INHBe for short term prophylaxis, acute treatment | pdC1-INHBe 15–30 units/kg/dose IV. | Expensive, currently unavailable in many Asian countries. One unit parallels the amount of C1INH in 1 ml of plasma of a normal individual. |
pdC1-INHCi for long term prophylaxis, acute treatment | pdC1-INHCi 10–20 units/kg/dose once or twice weekly (initial maximum dose 1000 units). | ||
rhC1-INH for acute treatment, long term prophylaxis | rhC1-INH 50 units/kg/dose and is given by intravenous injection. | ||
Subcutaneous preparations are also available. | |||
Ecallantide | Acute treatment | 30 mg/dose subcutaneous injection | Expensive, risk of anaphylaxis. Not available in many Asian countries. |
Icatibant | Acute treatment | 30 mg/dose subcutaneous injection (maximum three doses/day) | Expensive. Not available in many Asian countries. Local reactions. |
Lanadelumab | Long term prophylaxis | Dose range 150–300 mg every 2–4 weeks. | Pediatric dosing yet to be established. |
BCX7353 | Long term prophylaxis | Minimum effective dose used: 125 mg/day |